No matter how one tries to spin something into something that isn't, the current 42 million shares owned by OREO shareholders today will be 3.5% of the shares O/S after the reverse merger.
The market cap of those 42 million shares, which represents only an interest in a shell company, is $1.7 million. And that $1.7 million for a potential future 3.5% ownership in Avant Diagnostics compares to Arrayit Shareholders valuing their 55% interest at a couple million dollars.
IMHO - OREO could drop 95% just to reflect what would be the proper valuation of a 3.5% interest in Avant Diagnostics.
OREO has to do the reverse split because they can's issue 1.2 BILLION shares to Avant Shareholders since they are limited to 450,000,000 million shares.
Otherwise the simple transaction would be to issue 1.2 billion more shares for the reverse merger. The result is the same, the specifics are done to end up with 70 million shares O/S, 450 million shares AUTHORIZED and current OREO shareholders getting just 3.5% of the new entity, if the transaction goes through.
